Skip to main content
Premium Trial:

Request an Annual Quote

Clinical Pharmacogenetics Implementation Consortium Gets $5M in NIH Funding

NEW YORK (GenomeWeb) – The National Institutes of Health have awarded researchers at St. Jude Children's Research Hospital and Stanford University $5 million over the next five years for their continued work as part of the Clinical Pharmacogenetics Implementation Consortium.

CPIC develops guidelines on pharmacogenetic variants that healthcare providers can use to guide treatment and dosing decisions. Mary Relling, CPIC co-chair and St. Jude Pharmaceutical Sciences Department chair, said in a statement that the latest funding from the NIH is necessary to further advance pharmacogenetic testing into the clinic.

The funding will help CPIC continue its work creating and updating pharmacogenetics guidelines, adding drug-gene pairings, and creating electronic tables that can facilitate integration within electronic health records. CPIC also works with other stakeholders in the genomics community to coordinate efforts and align guidelines.

For example, CPIC worked with the Dutch Pharmacogenetics Working Group and around 30 experts to try to align genotype-to-phenotype translations for CYP2D6, one of the most widely tested pharmacogenetics genes.

"All of CPIC’s content is freely available on the CPIC website, and this funding will allow us to continue to update and expand this content,” said Teri Klein, CPIC co-chair from Stanford University.